Brief: Can-Fite Completes Patient Enrollment In Phase 2A Pancreatic Cancer Study Of Namodenoson
20/01/2026 12:38
Jan 20 (Reuters) - Can Fite Biopharma Ltd CANF.TA: CAN-FITE COMPLETES PATIENT ENROLLMENT IN PHASE 2A PANCREATIC CANCER STUDY OF NAMODENOSON CAN FITE BIOPHARMA LTD: PRIMARY SAFETY ENDPOINT DEMONSTRATED TO DATE; TOP-LINE EFFICACY DATA EXPECTED IN Q3 2026 Source text: ID:nGNXbhKJ5d Further company coverage: CANF.TA (Reporting by Kunal Das) ((Kunal.Das2@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage